Emerging work demonstrates the dual regulation of mitochondrial function by hydrogen sulfide (H2S), including, at lower concentrations, a stimulatory effect as an electron donor, and, at higher concentrations, an inhibitory effect on cytochrome C oxidase. In the current article, we overview the pathophysiological and therapeutic aspects of these processes. During cellular hypoxia/acidosis, the inhibitory effect of H2S on complex IV is enhanced, which may shift the balance of H2S from protective to deleterious. Several pathophysiological conditions are associated with an overproduction of H2S (e.g. sepsis), while in other disease states H2S levels and H2S bioavailability are reduced and its therapeutic replacement is warranted (e.g. diabetic vascular complications). Moreover, recent studies demonstrate that colorectal cancer cells up-regulate the H2S-producing enzyme cystathionine β-synthase (CBS), and utilize its product, H2S, as a metabolic fuel and tumour-cell survival factor; pharmacological CBS inhibition or genetic CBS silencing suppresses cancer cell bioenergetics and suppresses cell proliferation and cell chemotaxis. In the last chapter of the current article, we overview the field of H2S-induced therapeutic ‘suspended animation’, a concept in which a temporary pharmacological reduction in cell metabolism is achieved, producing a decreased oxygen demand for the experimental therapy of critical illness and/or organ transplantation.
This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue-8
ATP-sensitive potassium channel
H2S, a colourless, flammable, water-soluble gas, is gaining increased attention as an endogenous biological mediator. The distribution and regulation of the three H2S-producing enzymes [cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST)], and the wide range of biological effects of H2S are discussed in separate reviews (Fiorucci et al., 2006; Szabo, 2007; Calvert et al., 2010; Elsey et al., 2010; Gadalla and Snyder, 2010; Kimura, 2010; 2013; Predmore and Lefer, 2010; Whiteman and Winyard, 2011; Whiteman et al., 2011; Kimura et al., 2012; Wang, 2012). In a recent article, we have overviewed the dual mitochondrial effects of H2S, which range from stimulatory effects, occurring at lower concentrations, to the suppression of mitochondrial function, which occurs at higher concentrations (Szabo et al., 2013a). The purpose of the current article is to outline the physiological, pathophysiological and therapeutic aspects of this regulation. Similar to our approach in the companion article (Szabo et al., 2013a), in the current article we use the terms ‘sulfide’ and H2S interchangeably to collectively refer to H2S gas as well as its two ionized forms in solution: HS- and S2-.
H2S as a potential inducer of cytopathic hypoxia in circulatory shock
Various forms of circulatory shock lead to an intrinsic impairment of mitochondrial function, a phenomenon often called ‘cytopathic hypoxia’ (Fink, 2001; Levy, 2007; LaRosa and Opal, 2008). This phenomenon entails the intrinsic impairment of the mitochondria to utilize oxygen, and manifests itself in a narrow arteriovenous oxygen difference due to the inability of the ‘poisoned’ tissue to ‘extract’ oxygen during circulatory shock.
There are several lines of published studies using shock models induced by bacterial LPS, and by cecal ligation and puncture (CLP, a polymicrobial model of sepsis), showing overproduction of H2S and/or the beneficial effect of inhibitors of H2S production such as propargylglycine (PAG) (reviewed in Wagner et al., 2009; Coletta and Szabo, 2013). There are also several clinical studies demonstrating the overproduction of sulfide in patients with various forms of circulatory shock (Goslar et al., 2011). It is a logical assumption, therefore, that endogenously produced sulfide may contribute to the pathogenesis of cytopathic hypoxia in circulatory shock, especially in light of the findings showing that acidosis (a common feature of shock) enhances the inhibitory effect of sulfide on complex IV (Groeger et al., 2010; Szabo et al., 2013a). Nevertheless, the question whether endogenously produced sulfide contributes to cytopathic hypoxia has not yet been directly or comprehensively addressed; nor has it been explored how much the specific pattern of perfusion and oxygenation occurring in the tissue during the course of a shock state may modulate this response. For example, in a porcine model of haemorrhagic shock (Bracht et al., 2012b), it was found that a pronounced reduction of mitochondrial respiratory activity occurs in terms of oxygen flux (JO2) per amount of tissue in permeabilized skeletal muscle biopsies after 3 h of shock, when compared with the control before the haemorrhage (control, JO2 = 44 ± 12 [pmol/(s*mg tissue)] vs. 3 h shock, JO2 = 25 ± 7 [pmol/(s*mg tissue)], P < 0.001). However, 12 h of reperfusion allowed mitochondrial respiration to almost completely recover (JO2 = 40 ± 6 [pmol/(s*mg tissue)], P < 0.001), suggesting that mitochondria highly dynamically adapt to the actual circulatory and oxygenation conditions in this experimental model. Continuous infusion of the sulfide donor Na2S did not affect the response to shock and reperfusion (control, JO2 = 35 ± 13 [pmol/(s*mg tissue)] vs. 3 h shock, JO2 = 22 ± 8 [pmol/(s*mg tissue)], P < 0.001, and 12 h recovery, JO2 = 39 ± 15 [pmol/(s*mg tissue)], P < 0.001), suggesting that exogenously administered sulfide does not induce or exacerbate cytopathic hypoxia in this model. It is important to note that the direct answer as to whether endogenous sulfide contributes to the cytopathic hypoxia in circulatory shock would require studies in which H2S overproduction in shock is inhibited (by pharmacological tools or by genetically modified animals), followed by metabolic analysis of tissues ex vivo. Such studies have not yet been conducted.
Indirect lines of data, nevertheless, indicate that sulfide may have an impact on mitochondrial respiration during circulatory shock. For example, as shown in Figure 1, CLP-induced septic shock reduces the maximum mitochondrial respiratory capacity (ETS capacity) in the liver of mice, this effect being more pronounced under hypothermia than under normothermia (diagram A). Comparison of the respiratory activity compensating for the proton leak at the inner mitochondrial membrane (LEAK respiration) with the OxPhos capacity to the maximum respiration in the uncoupled (ETS) state (L/E and P/E ratios, respectively, diagram C) reveals that the reduction of maximum mitochondrial respiratory capacity is pronounced even under normothermic conditions. Interestingly, treating the animals with sulfide fully compensated for these CLP-related effects, thus maintaining normal mitochondrial activity regardless of body temperature in septic shock (diagrams B and D). These findings would be consistent with a therapeutic effect of exogenous sulfide administration, rather than a potential causative role of sulfide in inducing cytopathic hypoxia in shock. The different effects of sulfide under normo- and hypothermia are clearly explained by the strong temperature-dependent inhibition of mitochondrial respiration by sulfide, which is much weaker at low body temperature (Baumgart et al., 2010).
The study of combined hypothermia and sulfide is interesting because both of these interventions have been previously linked to metabolic suppression, and the combination of them may offer therapeutic possibilities in the context of ‘on-demand suspended animation’ (see below). Hypothermia not only assumes the importance for H2S-induced inhibition of mitochondrial respiration, but also markedly influences substrate utilization and thereby may even improve the activity of the mitochondrial respiratory chain. In anaesthetized and ventilated mice, inhaling 100 p.p.m. H2S did not affect endogenous glucose production (as calculated from the rate of appearance of 1,2,3,4,5,6-13C6-glucose during continuous i.v. isotope infusion), whole body CO2 production, or direct, aerobic glucose oxidation rate (as derived from VCO2 and the expiratory 13CO2/12CO2 ratio) during normothermia. However, combining inhaled H2S with hypothermia (core temperature 27°C) increased glucose oxidation, suggesting a shift towards preferential carbohydrate utilization (Figure 2) (Baumgart et al., 2010). Such a switch in fuel utilization is associated with an improved yield of oxidative phosphorylation (Korvald et al., 2000): the ATP synthesis/oxygen consumption ratio is higher for glycolysis than for oxidation because NADH (as an electron donor) provides three coupling sites rather than the two that FADH2 provides (Leverve, 2007). This effect on substrate metabolism coincides with a significantly attenuated responsiveness of hepatic mitochondrial respiration to stimulation with exogenous cytochrome C oxidase, that is, an improved maintenance of the outer mitochondrial membrane (Kuznetsov et al., 2004). It should be noted, however, that this protective effect of inhaled H2S partially disappeared during CLP-induced septic shock: not only did inhaled H2S not affect the sepsis-induced metabolic acidosis (Wagner et al., 2011). Finally, during sepsis, inhaled H2S did not improve the responsiveness to stimulation with exogenous cytochrome-c-oxidase either. It remains open whether the lacking effects of H2S on substrate utilization were due to the sepsis per se and/or the ongoing noradrenaline infusion needed to maintain target haemodynamics: noradrenaline causes oxidative stress and may inhibit mitochondrial respiration (Bracht et al., 2012a).
Taken together, the above data, as well as multiple prior studies with sulfide donation or sulfide inhibition (reviewed in Wagner et al., 2009; Coletta and Szabo, 2013), reveal a complex, and only partially understood, regulation of sulfide in circulatory shock. While in some experimental models sulfide donation is clearly beneficial, in other models, sulfide donation actually exacerbates the outcome. In yet other models, however, pharmacological inhibitors of sulfide biosynthesis are therapeutically effective. These findings may reflect the diversity of the roles of sulfide in various models, forms and stages of shock (ranging from sulfide deficiency to sulfide overproduction), and may also relate to tissue/organ-specific differences or species-specific differences, as well as may be related to the complex, biphasic or bell-shaped biological effects of sulfide. Clearly, additional work needs to be conducted in this area, and it needs to be directly tested whether endogenously produced sulfide contributes to cytopathic hypoxia in certain models. In addition, further work needs to be conducted to test whether metabolic effects or mitochondrial protective mechanisms contribute to the therapeutic effects of sulfide donation in those models where sulfide administration was found beneficial.
H2S as a mitochondrial protectant in diabetes
Chronic or intermittent elevations in circulating glucose concentration damage the blood vessels, especially the innermost cell layer, the endothelium. Diabetic endothelial dysfunction is now recognized as a central pathophysiological event in the development of many, if not all, complications of diabetes, ranging from vascular events (peripheral vascular disease, coronary artery disease, diabetic retinopathy, diabetic neuropathy) to other diabetic complications such as impaired wound healing, cardiomyopathy and male erectile dysfunction (Szabo, 2005; 2009; Pacher and Szabo, 2006; Horváth et al., 2009; Rosenson et al., 2011; Shin et al., 2011; Stitt et al., 2013).
The mechanisms and experimental therapy of diabetic/hyperglycaemic endothelial dysfunction have been characterized in significant detail. Several lines of studies show that elevated extracellular glucose induces mitochondrial dysfunction in endothelial cells (Nishikawa et al., 2000; Du et al., 2003; Giacco and Brownlee, 2010; Gerö et al., 2013). On one hand, this entails the suppression of cellular bioenergetics through the impairment of the mitochondrial electron transport/ATP generation (Sivitz and Yorek, 2010; Pangare and Makino, 2012). On the other hand, intracellular production of reactive oxygen and nitrogen species from the dysfunctional mitochondria initiates multiple pathways of pro-inflammatory signalling (Nishikawa et al., 2000; Du et al., 2003; Giacco and Brownlee, 2010), as well as deleterious, self-amplifying cycles of cell injury such as the activation of the nuclear enzyme PARP (Garcia Soriano et al., 2001; Horváth et al., 2009).
Several lines of studies demonstrate that hydrogen sulfide exerts protective effects against the development of diabetic complications (reviewed in Szabo, 2012), at least in part by protecting the diabetic mitochondria. Circulating sulfide levels are decreased in diabetes, in part due to an increased consumption of sulfide by reactive oxygen species (ROS) production and in part due to the down-regulation of CSE, the principal H2S-producing enzyme in endothelial cells (Brancaleone et al., 2008; Jain et al., 2010; Whiteman et al., 2010; Suzuki et al., 2011; Kundu et al., 2013; Yamamoto et al., 2013). These events are paralleled with impaired cellular bioenergetics as well as reduced endothelium-dependent relaxant responses and increased pro-inflammatory signalling events, ultimately leading to cell death. Silencing of CSE further exacerbates the hyperglycaemic ROS production, while supplementation of CBS (by pharmacological tools or by overexpression of H2S-producing enzymes) suppresses it (Suzuki et al., 2011). Pharmacological supplementation or genetic expression of H2S-producing enzymes in cells subjected to hyperglycaemia reduces mitochondrial ROS formation (Suzuki et al., 2011; Guan et al., 2012; Zhong et al., 2012; Zhou and Lu, 2013) and exerts cytoprotective effects (Suzuki et al., 2011), including a partial normalization of mitochondrial bioenergetics (restoration of oxidative phosphorylation and inhibition of glycolysis, which is elevated in hyperglycaemic endothelial cells as a compensatory mechanism) (Suzuki et al., 2011) (Figure 3). Sulfide also protects against the activation of pro-inflammatory signalling pathways in hyperglycaemic endothelial cells (e.g. NF-κB activation, inflammatory cytokine production) (Guan et al., 2013; Manna and Jain, 2013; Si et al., 2013), reduction in matrix protein synthesis/protection against remodelling (Yuan et al., 2011; Lee et al., 2012; Kundu et al., 2013), as well as against the activation of PARP (Suzuki et al., 2011). The beneficial effects of sulfide supplementation have also been demonstrated in multiple models of diabetes in vivo, resulting in improved cardiac contractility, improved endothelium-dependent relaxations, and improved retinal and renal function and histopathology (Gao et al., 2011; Suzuki et al., 2011; Yang et al., 2011; Ahmad et al., 2012; Zhong et al., 2012; Si et al., 2013; Yamamoto et al., 2013). Given the fact that the direct reaction of H2S with various oxidant species is relatively slow (Carballal et al., 2011) and is outcompeted by many other reactions in the mitochondrion, it is likely that indirect antioxidant effects (e.g. via the regulation of signalling processes and/or via up-regulation of various antioxidant pathways) are also involved in the observed mitochondrial protective effects of sulfide. The beneficial effects on bioenergetic/mitochondrial processes are likely to play a role in the therapeutic effect of H2S in diabetic complication models. However, it is likely that additional effects of H2S (on signal transduction, redox balance and, perhaps, vasodilatory/haemodynamic effects) also contribute.
H2S as endogenously produced metabolic ‘fuel’ in cancer cells
Cellular bioenergetics is essential for invasive tumour growth and metastasis and constitutes a key point in the control of cancer progression (Pathania et al., 2009; VanderHeiden et al., 2009; Ramsay et al., 2011; Bailey et al., 2012). Tumour cells rely both on oxidative phosphorylation (mitochondrial activity) and on increased glycolytic activity (‘aerobic glycolysis’ to produce ATP), which is used to support tumour cell growth, division cell movement. Tumour cell bioenergetics is intricately intertwined with pro-inflammatory and pro-growth tumour cell signalling processes (Cairns et al., 2011; Schulze and Harris, 2012). Therapeutic targeting of tumour cell energetics – especially using approaches that confer selectivity to the tumour cell – is an emerging concept in contemporary cancer therapy (Ramsay et al., 2011; Bailey et al., 2012).
Recent data from a colorectal cancer models indicate that cancer cells can utilize H2S as an endogenous bioenergetic ‘fuel’ (Szabo et al., 2013b). A comparison of human colon cancer specimens with patient-matched normal mucosa tissue revealed the selective up-regulation of CBS in the cancers. In contrast, the expression of the other two H2S-producing enzymes (CSE and 3-MST) remained unchanged. Similar to colon tumours, colon adenocarcinoma-derived cell lines (HCT116, HT-29, LoVo) exhibit selective up-regulation of CBS when compared with NCM356 cells (a non-tumorigenic control human epithelial cell line) (Figure 4A,B). Homogenates of the patient-derived colon tumour specimens, as well as homogenates of the colon cancer-derived cell lines, exhibit an increased rate of H2S production, which is blocked by the CBS inhibitor aminooxyacetic acid (AOAA), a widely used CBS inhibitor (Abe and Kimura, 1996; Julian et al., 2002; Austgen et al., 2011; Han et al., 2011; Asimakopoulou et al., 2013; Rashid et al., 2013; Wang et al., 2013). However, H2S production was not significantly inhibited by the CSE inhibitor PAG. (For additional discussion on the limitations of pharmacological inhibitors of CBS and CSE, see the final section of the current article.)
To investigate the functional consequence of CBS up-regulation, gene-specific shRNA sequences in lentiviral vectors were used to suppress the expression of either CBS or CSE in HCT116 cells. Densitometric analyses of Western blots revealed an approximately 50% decrease in CBS expression with comparable reductions in both cell proliferation and H2S production (Figure 4C). In contrast to CBS, silencing of CSE or its inhibition by PAG did not significantly affect either HCT116 cell proliferation or H2S production (Szabo et al., 2013b). To further define the function of CBS in colon cancer cells, both NCM356 cells (which express CSE, but only low levels of CBS) were treated and HCT116 cells (which abundantly express CBS) with the pharmacological CBS inhibitor, AOAA. Consistent with the CBS knock-down experiments, AOAA has also been utilized. AOAA inhibited the growth of HCT116 colon cancer cells, but did not affect the proliferation of the slower growing non-malignant NCM356 cell line (Szabo et al., 2013b) (Figure 4D). Conversely, forced overexpression of CBS in NCM356 cells significantly increased their basal rate of proliferation (Figure 4E). AOAA treatment also suppressed the migration and invasion of HCT116 cells. Finally, inhibition of CBS with AOAA reduced endothelial cell migration in colon cancer/endothelial cell co-cultures (Szabo et al., 2013b).
The above data demonstrated that CBS and CBS-derived H2S play an important role in promoting tumour cell proliferation. In the context of the current article, the most relevant question is the following: What role, if any, do H2S-associated energetic alterations play in these actions? In order to answer this question, HCT116 colonic cancer cells, and NCM356 cells as non-transformed controls, were subjected to bioenergetic measurements using the Extracellular Flux Analysis (Szabo et al., 2013b). In agreement with the physiological role of endogenous H2S in promoting cellular bioenergetics in various cell types including colonocytes (reviewed in Szabo et al., 2013a), low concentrations of H2S caused a stimulation of mitochondrial function in mitochondria isolated from HCT116 cells. Moreover, shRNA-mediated silencing of CBS, or CBS inhibition with AOAA, reduced basal cellular respiration, suppressed the calculated ATP synthesis and attenuated the spare respiratory capacity (Figure 5A–C). CBS silencing or CBS inhibition also reduced glycolytic functions, while CSE silencing was without significant effect (Figure 5D). This latter effect can be attributed, at least in part, to inhibition of GAPDH activity, as H2S is known to be an activator of GAPDH via sulfhydration (Mustafa et al., 2009; Paul and Snyder, 2012). In mitochondria prepared from HCT116 cells, L-cysteine stimulated mitochondrial electron transport; this effect was markedly attenuated in mitochondria prepared from shCBS cell expression (Szabo et al., 2013b). In AOAA-treated mitochondria (which showed suppressed electron transport), sulfide addition improved and restored mitochondrial function (Figure 6). This mitochondrion-autonomous response was consistent with the results of cell fractionation studies, showing that a significant portion of the total amount of cellular CBS was associated with the mitochondria in HCT116 cells. CBS was primary associated with the outer mitochondrial membrane (Szabo et al., 2013b).
These findings indicate that endogenous sulfide, produced from CBS, stimulates tumour cell bioenergetics (both oxidative phosphorylation and glycolysis). The effect CBS silencing or CBS inhibition has on tumour progression in vivo has also been investigated by utilizing nude mice subjected to heterotopic transplantation of either HCT116 cells or patient-derived colon cancer xenografts (Szabo et al., 2013b). Consistent with the in vitro findings showing that CBS inhibition suppresses tumour cell proliferation, shRNA-mediated knock-down of CBS expression (shCBS) or treatment of the mice with AOAA significantly reduced the growth rate and size (i.e. volume) of HCT116 tumour xenografts (Szabo et al., 2013b). In contrast, silencing of CSE (shCSE) or pharmacological inhibition of CSE with PAG did not affect tumour growth. CBS suppression caused a significant reduction in the density of CD31-positive blood vessels within the tumour tissue as well as the prevalence of larger blood vessels and the extent of vessel branching, consistent with the hypothesis that CBS-derived H2S acts locally in a paracrine manner to stimulate tumour angiogenesis (Szabo et al., 2013b); the pro-angiogenic role of H2S is supported by multiple lines of in vitro and in vivo studies (Cai et al., 2007; Papapetropoulos et al., 2009; Szabo and Papapetropoulos, 2011; Coletta et al., 2012). Finally, in a series of translational studies, AOAA treatment showed a reduced rate of the growth of patient-derived tumour transplants (Szabo et al., 2013b).
Taken together, these data support the hypothesis that CBS-derived endogenously produced H2S plays a key role in cancer cell bioenergetics and cell proliferation via autocrine mechanisms. Moreover, via paracrine mechanisms, H2S also supports tumour angiogenesis and acts as a local vasodilator, thereby stimulating the supply of the tumour with nutrients via the bloodstream (Figure 7). Several independent lines of studies show that H2S can produce an activation of kinase pathways and inhibition of phosphatase pathways (Cai et al., 2007; 2010; Hu et al., 2008; 2011; Krishnan et al., 2011; Manna and Jain, 2011), leading to the regulation of the cell cycle (Deplancke and Gaskins, 2003; Cai et al., 2010). Because these pathways are crucial contributors to tumour cell proliferation, it is conceivable that such effects may also contribute to the proliferative effects of the CBS/H2S axis in colorectal tumours (and possibly other tumours as well).
To put the above findings in the context of prior findings in the literature, it is interesting to note that a number of papers have previously reported that CBS expression is increased in various tumours (Goss, 1986; Zhang et al., 2005; Guo et al., 2012a). Moreover, in one prior study, CBS expression has been associated with increased cell proliferation (MacLean et al., 2002) (even though none of these prior investigations raised the potential involvement of H2S). In addition, several studies demonstrated increased H2S production in the exhaled air and flatus of cancer patients (Kumar et al., 2012; Yamagishi et al., 2012; Altomare et al., 2013) and increased urinary excretion of thiosulfate, the stable breakdown product of H2S (Chwatko et al., 2013) (even though these investigations have not identified the enzymatic source). Finally, several recent studies noted the inhibitory effect of AOAA on cancer cell proliferation in vitro and/or in vivo (Thornburg et al., 2008; Weinberg et al., 2010; Anso et al., 2013; Son et al., 2013) (even though these investigators attributed the effects of AOAA to pharmacological actions other than CBS inhibition).
The pharmacology of AOAA is, indeed, complex. This compound is generally known as a non-specific inhibitor of transaminases. It inhibits the activity of these enzymes because it irreversibly binds to the prosthetic group pyridoxal phosphate, which is commonly found in the active site of transaminases. In the context of recent studies, its inhibitory effect on GOT1 [an essential component of the malate/aspartate shuttle, a mechanism that links glycolysis to the transfer of electron donors into the mitochondria of cancer cells (Greenhouse and Lehninger, 1976; 1977; Dang et al., 2011)] has been linked to antitumor actions (Thornburg et al., 2008). In addition, the function of GOT1 is linked to glutaminolysis, a metabolic pathway that is at least partially selective to cancer cells (and, hence, may be therapeutically targetable) (Le et al., 2012; Son et al., 2013); AOAA has been shown to inhibit the metabolic activity of cancer cells by interfering with glutaminolysis (Son et al., 2013). The studies discussed above show that CBS/H2S production can also be considered as a partially cancer-selective metabolic pathway. It can be argued that with AOAA, one can simultaneously block the energetic ‘fuelling’ of the cancer cell via the malate/aspartate shuttle and the energetic ‘fuelling’ of the cancer cell via the CBS/sulfide route (Figure 8), thereby inducing ‘synthetic lethality’ with two independent pharmacological effects of a single compound. In order to compare the effects of AOAA with the effects of glycolysis inhibition and inhibition of ATP synthase, we have evaluated the effect of the glycolysis inhibitor 2-deoxyglucose, the ATP synthase inhibitor oligomycin, and AOAA (alone and in various combinations) on ATP levels in HCT116 tumour cells. AOAA reduced ATP levels to 80% of control, whereas oligomycin reduced them to 71%. Addition of AOAA to oligomycin did not exert a substantial further inhibitory effect. Likewise, addition of AOAA to 2-deoxyglucose (which, on its own, reduced ATP levels to 45%) did not further inhibit cellular ATP levels (Figure 9). These findings point to a coordinated interaction between sulfide-dependent modulation of both oxidative phosphorylation and glycolysis; in both cases more likely in a role as an enhancer/potentiator, rather than an independent activator. It must also be emphasized that the effects of sulfide in cancer cells are likely to be more complex and are likely to include additional effects beyond mitochondrial function (such as effects on glycolysis) as well as pharmacological effects beyond bioenergetics (such as effects on kinase pathways and cell cycle). While it is clear that much further work needs to be conducted in this area, the above series of studies may open a previously unexplored, and potentially clinically translatable aspect of tumour biology.
The mechanism of the up-regulation of CBS in colon cancer cells is not known. Possibilities include a transcriptional up-regulation, a blockade of its degradation, or targeted delivery to the mitochondria via not yet understood mechanisms. A recent study by Teng and colleagues demonstrating in ischaemic liver and in hypoxic hepatocytes that CBS is targeted to the mitochondria via the hypoxia-sensitive regulation of the mitochondrial matrix protease L on protease (Teng et al., 2013) offers a plausible mechanism (especially in light of the well-known phenomenon of tumour hypoxia), which, nevertheless, remains to be directly tested in future studies.
We are well aware of reports in the literature, demonstrating that it is H2S donation (rather than H2S biosynthesis inhibition) that can kill cancer cells (e.g. Shin et al., 2010; Lee et al., 2011; Chattopadhyay et al., 2012a,b; Lim et al., 2012). These studies tend to use relatively high concentrations of various H2S donors, often linked with molecular scaffolds that have their own sulfide-independent pharmacological actions (e.g. NOSH-aspirin, which has a non-steroidal anti-inflammatory component). These findings are in no way in conflict with the findings related to the bioenergetic and pro-angiogenic effects of endogenously produced H2S in cancer cells, but, rather, illustrate the complex pharmacology of H2S, where low concentrations/fluxes of the mediator and higher concentrations/release rates of the same mediator can have radically different biological effects (as discussed in Szabo et al., 2013a). The interpretation of the findings related to the anticancer effect of H2S donors may therefore be related to the high concentrations of H2S used, at which concentrations H2S has cytostatic and cytotoxic properties (possibly, at least in part related to the inhibition of mitochondrial electron transport chain system at complex IV). We predict that one of the technical hurdles of exploiting therapeutic H2S donation for anticancer therapy will be the delivery: one needs to generate high local levels of H2S, for reasonably prolonged time, in order to produce anticancer effects. It is hoped that further studies will solve this issue; a similar problem has previously arisen in the context of NO donation and anticancer therapy (NO, too, has bell-shaped dose responses and vital, physiological effects at low concentrations and cytostatic effects at higher concentrations). In this context, photodynamic therapy, with NO-releasing photolabile molecules, has been put forward as one possible technical solution (Bhowmick and Girotti, 2013; Rapozzi et al., 2013).
Therapeutic induction of ‘on-demand suspended animation’ with H2S
One of the most fascinating biological features of H2S is the ‘suspended animation-like state’ that it can induce. The landmark paper on that subject (Blackstone et al., 2005), which utilized gaseous H2S to induce a hibernation-like state, has sparked interest in the use of sulfide as an inducer of hypometabolism to protect organs and cells against temporary insults. By exposing mice to subtoxic concentrations of H2S (20–80 p.p.m.), a concentration-dependent state of deeply reduced metabolism was induced, as evidenced by a fast reduction of total-body CO2 production and O2 consumption (60–70% within 5–10 min), followed by a slow decline of metabolism to around 5% of basal levels. This slower decline parallels the reduction in body temperature that follows the exposure. Core body temperature steadily declines to around 2°C above ambient temperature over the course of hours. After cessation of H2S exposure, metabolism recovers to basal levels with no apparent toxic effects (Blackstone et al., 2005). The sulfide-mediated reduction of metabolic demand has been shown to protect mice against the mortality associated with otherwise lethal hypoxia (Blackstone and Roth, 2007).
Although the above findings of metabolic suppression have been repeatedly confirmed in mice (Blackstone and Roth, 2007; Volpato et al., 2008; Bos et al., 2009) ( Figure 10), it has been challenging to translate these findings to larger mammals. Different studies have been performed with varying results. Some studies showed no effect on metabolic parameters in rats (Haouzi et al., 2009), sheep (Haouzi et al., 2008) or swine (Li et al., 2008; Drabek et al., 2011), while others showed metabolic suppression in rats (Florian et al., 2008; Aslami et al., 2010; 2013a; Seitz et al., 2012) and swine (Simon et al., 2008). One human toxicity study shows that inhalation of 10 p.p.m. H2S during exercise reduces V·O2, possibly by reducing aerobic capacity (Bhambhani et al., 1997). A comparison of the effects of sulfide to the effects of anaesthetics shows that H2S does not have the hypnotic or immobilizing effects of anaesthetic compounds (Li et al., 2012). The last word has not been written on the interspecies variability, but it seems that the translation to larger mammals is more difficult than initially presumed. A possible explanation lies in the different types of metabolism between smaller and larger animals. Mice have a relatively high metabolic rate in relation to their body weight, and a larger proportion of their metabolism is geared towards maintaining core body temperature. It is well established that in response to hypoxia, small rodents can reduce their energy expenditure by decreasing ‘non-shivering thermogenesis’, irrespective of any pharmacological intervention. Hypoxia-induced hypometabolism is present in numerous mammals (Mortola, 2004) and humans (van Marken Lichtenbelt and Schrauwen, 2011), but due to the high area/volume ratio and, consequently, the higher heat dissipation, it is inversely related to body size (Mortola, 2004), that is, to the ratio of O2 consumption and body weight (VO2/kg). This is substantiated by the fact that (i) no matter the species, newborns present with more pronounced hypoxia-induced hypometabolism than adults, and (ii) in adults with low VO2/kg, hypoxia-induced hypometabolism becomes manifest when normoxic VO2 is increased, for example, during exercise (Mortola, 2004). Because non-shivering thermogenesis does not result in ATP production due to the activity of uncoupling proteins (van Marken Lichtenbelt and Schrauwen, 2011), reduced VO2 and the consecutive hypothermia represent a unique adaptation to hypoxia only present in small animals but not in larger species or humans. Consequently, with respect to the putative induction of a ‘suspended animation'-like hypometabolism, it has been questioned whether any therapeutic potential of H2S observed in mice and rats can be transferred to the clinical setting (Leslie, 2008, Derwall et al., 2010, Drabek et al., 2011, Haouzi, 2011; 2012). Clearly, data in sheep and swine subjected to shock, ischaemia/reperfusion (Sodha et al., 2008; Osipov et al., 2009; Sodha et al., 2009; Osipov et al., 2010; Simon et al., 2011; Hunter et al., 2012), haemorrhage (Bracht et al., 2012b) or burn injury (Esechie et al., 2009) suggest that the beneficial effects of infusing Na2S are independent of core temperature: any induction of moderate hypothermia is due to an attenuation of systemic inflammation rather than an effect on energy expenditure (Simon et al., 2011; Bracht et al., 2012b). Further studies need to be conducted to study dose responses and to compare different methods of administration (i.e. gaseous, i.v./i.a. soluble salt injection, slow release donor injection).
Sulfide-induced hypometabolism is highly protective in different models of hypoxia or ischaemia. During H2S-hypometabolism, mice can survive hypoxia (5% O2) for up to 6 h, while all the animals in the control group died within 17 min (Blackstone and Roth, 2007). Similarly, hydrogen sulfide-induced hypometabolism has been shown to improve survival in lethal haemorrhagic shock in the rat; the mechanism has been attributed to suppression of tissue oxygen demand by sulfide (Morrison et al., 2008). Tokuda and colleagues have reported that inhaled H2S gas suppresses inflammatory response and prolongs survival in endotoxin shock, effects that have been attributed to suppression of metabolism (Tokuda et al., 2012). Inducing a state of hypometabolism using 100 p.p.m. H2S before clamping the renal artery can prevent the onset of kidney damage in mice ( Figure 11 and Figure 12) (Bos et al., 2009). Induction of hypometabolism during the reperfusion phase has some protective potency, but much less than pretreatment does (Bos et al., 2009). Similar results were obtained for hepatic ischaemia, in which hypometabolic pretreatment protected livers from ischaemic damage (Bos et al., 2012). In both of these studies, hypometabolism was induced while core body temperature was kept at 37°C (thus preventing hypothermia). This shows that hypothermia itself is not needed for hypometabolic protection (but, in theory, it could offer additional protection). H2S-induced hypometabolism, when established before the onset of ischaemia, was also protective in cardiac ischaemia (Snijder et al., 2013). Sub-hypometabolic concentrations of H2S are mainly associated with anti-inflammatory and anti-fibrotic action, while higher concentrations of H2S (those that induce hypometabolism) offer additional protection against early myocardial necrosis.
It is likely that the protective effects of H2S can be attributed to several factors, hypometabolism being just one of them. As noted in the previous sections, H2S has many pharmacological effects in addition to metabolic suppression, as it can act as an anti-oxidant, anti-fibrotic, anti-inflammatory and anti-apoptotic substance (Zanardo et al., 2006; Yao et al., 2010; Bos et al., 2013; Snijder et al., 2013). In addition, treatment with H2S during hypoxia protects the integrity and function of mitochondria (Elrod et al., 2007; Bos et al., 2009).
Although it is of a mixed pharmacological action, sulfide remains to be an intriguing molecule as an on-demand inducer of hypometabolism, with the capability to protect organs from ischaemia or hypoxia. Several sets of studies show the ability of sulfide to hibernate isolated organs which could be promising in the setting of organ transplantation, where warm and cold ischaemia times affect transplant survival and function (Table 1, Figure 12) (Hu et al., 2007; Henderson et al., 2010; Hosgood and Nicholson, 2010; Balaban et al., 2011; Bos et al., 2012; George et al., 2012; Hunter et al., 2012; Lobb et al., 2012; Siriussawakul et al., 2012; Xie et al., 2012; Zhu et al., 2012; Wu et al., 2013). In addition, hypometabolic effects (if they prove to be translatable to large animals and humans) could be of potential use in other clinical situations as well, such as vascular surgery, infarction and stroke.
|Heart||Isolated rat hearts; Langendorff perfusion system; Krebs–Henseleit solution. Cold heart storage for 6 h, followed by warm reperfusion for 30 min with or without sulfide (1 μM).||Sulfide accelerated the recovery of contractility during reperfusion, improved myocardial contractility, increased ATP content and decreased myocardial apoptosis index.||Hu et al., 2007.|
|Lung||Rabbit heart/lung blocs stored in cold low-potassium dextrane sulfate solution for 18 h, followed by a 2 h reperfusion with donor blood in an in vitro perfusion system. Lungs from donor animals ventilated with room were compared with lungs of donor animals ventilated for 1 h with 150 p.p.m. H2S prior to the start of the excision/storage of the heart/lung blocs.||Perfusion pressures were improved in the sulfide group. In addition, H2S-treated lungs had better oxygenation and ventilation indices. Finally, sulfide treatment reduced ROS formation during reperfusion and resulted in a better maintenance of mitochondrial cytochrome c content.||George et al., 2012.|
|Rabbit heart/lung blocs stored in cold Perfadex solution for 18 h, followed by a 2 h reperfusion with donor blood in an in vitro perfusion system in the presence or absence of a bolus dose of NaHS (100 μg·kg−1 bolus + 1 mg·kg−1·h−1 infusion) starting at reperfusion.||Sulfide treatment reduced reactive oxygen species formation during reperfusion. Perfusion pressures were similar in all groups.||George et al., 2012.|
|Single left lung transplantation in rats, with 3 h of cold storage/ischaemia. NaHS was administered to the recipient animal at 14 μmol·kg−1 15 min before the start of the transplantation.||Sulfide improved pulmonary function (e.g. PaO2/FiO2 ratio) and pulmonary histology, reduced lung oedema formation and reduced the accumulation of neutrophils in the lung. Sulfide resulted in a reduction in IL-1β and an increase in IL-10 levels.||Wu et al., 2013.|
|Kidney||Porcine kidneys subjected to 25 min of warm ischaemia followed by 18 h of cold storage on ice after perfusion with a hyperosmolar citrate solution. Sulfide (or vehicle treatment) was applied as 0.5 mM NaHS infused 10 min prior and during reperfusion in an in vitro perfusion system.||Renal blood flow and renal function (measured as creatinine clearance, fractional excretion of sodium and urine output) was improved in the sulfide group. Sulfide treatment also resulted in reduced isoprostane and NO levels. No significant differences were observed in histological parameters between groups.||Hosgood and Nicholson, 2010.|
|Liver||Cold storage of rat livers in Wisconsin solution for 48 h, in the presence or absence of the sulfide donor diallyl disulfide (3.4 mM), followed by perfusion in an isolated constant-pressure perfusion system.||Hepatic clearance (bromosulfophthalein depuration) was enhanced by sulfide treatment; most other parameters (vascular resistance, oxygen consumption, LDH release as an index of cell injury) were unaffected by sulfide.||Balaban et al., 2011.|
|Cutaneous tissue||In vitro model of cutaneous tissue transplantation: endothelial cells and fibroblasts exposed to hypoxia or anoxia for 24 h, followed by 6 h of normoxia, in the absence or presence of NaHS (10 μM-1 mM).||Sulfide reduced apoptotic index (percentage of TUNEL-positive cells).||Henderson et al., 2010.|
|Stem cells||In vitro model of stem cell transplantation: rat mesenchymal stem cells exposed to hypoxia or anoxia for 6 h, in the absence or presence of NaHS (200 μM), followed by intramyocardial injection of stem cells and measurement of cardiac function in an ischaemia/reperfusion model in the rat.||Sulfide reduced hypoxia-induced stem cell apoptosis and enhanced donor cell survival in the heart after intramyocardial injection, resulting in improved cardiac contractility. Sulfide treatment was associated with increased Akt, Erk and GSK-3β activation in the stem cells, which has been suggested to contribute to the functional changes observed in vivo.||Xie et al., 2012.|
Therapeutic sulfide administration: pharmacological and biochemical considerations
The unique characteristics of the bioenergetic consequences of sulfide exposure must be carefully considered when designing experimental therapeutic approaches related to its administration. The same characteristics of sulfide must also be considered in formulating a critical analysis of the published findings showing the biological effects of sulfide administration in vitro or in vivo. With regard to in vitro models versus in vivo models, first of all it must be recalled that – while mammalian cells in vivo cannot survive for more than a few minutes when oxidative bioenergetics (i.e. mitochondrial function) is shut off (e.g. complete tissue ischaemia or severe cyanide poisoning) – the vast majority of mammalian cells in culture can survive to a prolonged eclipse or even a permanent inactivation of mitochondrial bioenergetics, if glucose concentrations are sufficient to sustain an intense anaerobic glycolysis. [Part of this may be explained by the fact that most cells grown in culture are transformed cells, with an up-regulation of glycolysis (Warburg effect).] It must therefore be kept in mind that cultured cells can, in fact, tolerate a severe transient or even permanent shutdown of mitochondrial function by high doses/steady rates of sulfide exposure, without impairing cell viability. (In fact, some cultured cells can even tolerate combined oxygen/glucose deprivation fairly well by mobilizing emergency pathways of ATP generation, e.g. by metabolizing purine nucleotides via adenosine kinase; Módis et al., 2009; Szoleczky et al., 2012). At the same time, such gross alterations in mitochondrial function may, in fact, initiate mitochondrion-mediated stress signalling. It has been suggested (Whitfield et al., 2008; Olson and Whitfield, 2010; Olson, 2012) that transient inhibitory effects of sulfide on mitochondrial electron transport may, in fact, be at least in part responsible for some of the observed cytoprotective effects of sulfide in vitro (and possibly in some of the in vivo studies as well). In other words, experiments aiming to promote or explain a sulfide-based pharmacological treatment have thus to be considered with regard to the mitochondrial bioenergetics. The first issue is whether or not a partially toxic concentration (tenth of micromolar) has been reached. If so, the cells concerned would experience something similar to an ischaemic period (sulfide toxicity period) followed by a reperfusion-like episode in which sulfide concentration would be brought back to non-toxic levels. In this case, complex cellular responses such as those induced by a drop in the ATP/ADP ratio would be triggered and while mobilization of such defences might be of interest (as they induce subsequent protection via preconditioning) the physiological responses would not necessarily represent specific ‘sulfide-signalling’ events. An indirect support of this hypothesis is that, so far, all of the pathways identified as downstream effectors of sulfide-mediated preconditioning (e.g. Nrf2, KATP channels, etc.) are, in fact, largely identical to the ones involved in the protective effect of all other forms of preconditioning (e.g. ischaemic, free radical/oxidant mediated, etc.) (e.g. Broadhead et al., 2004; Halestrap et al., 2007; Sadat, 2009; Yang et al., 2010; Bell et al., 2011). An alternative interpretation of the above-listed mechanisms may be, however, that sulfide (and possibly other gaseous transmitters) maintain a ‘controlled, adverse bioenergetic effect’ that may control cell signalling, cell viability and/or cardiovascular function.
With respect to the implications of the above mechanisms for in vivo experiments, similar considerations can be made. With a bolus administration of sulfide (or a short-acting sulfide donor), the fact that the animal tolerated the sulfide exposure means that a critical toxic concentration of sulfide was not reached/maintained for a significant amount of time in the vicinity of cells that control vital biological functions (such as a set of neurons controlling basic physiological functions). After entering the circulation, due to its diffusive properties, free sulfide will quickly distribute into the entire organism, where the cells equipped with the sulfide-oxidizing unit (SOU) will tend to metabolize it to low levels. [Part of the circulating sulfide may also exit in the gas phase via the lungs (Insko et al., 2009; Toombs et al., 2010).] We estimate that with fast-acting sulfide donors (sulfide salts), the rise in sulfide concentration compatible with survival probably does not exceed a few tenths of a micromolar for a few minutes. The resulting transient inhibition of mitochondrial function, and the subsequent preconditioning-type responses would then (similar to the in vitro considerations detailed in the previous paragraph) be expected to be at least in part responsible for subsequent protective/beneficial biological effects. When administering long-acting sulfide donors, or when applying a continuous infusion of short-acting hydrogen sulfide donors (e.g. infusion of H2S gas dissolved in physiological solutions), the above-mentioned ‘peak effects’ would not occur. In the latter case, steady-state levels of circulating sulfide would be maintained when equilibrium exists between sulfide administration (or the release rate of the sulfide donor) and the rate of sulfide elimination (i.e. overall sulfide-oxidizing capacities of the animal plus sulfide exhalation). An extreme example illustrates the biological consequences of impaired sulfide elimination: genetic deletion of ETHE1 (encoding for a β-lactamase-like, iron-coordinating metalloprotein, with sulfur dioxygenase activity) in mice results in a severe, toxic accumulation of sulfide, producing a severe inhibition of cytochrome c oxidase activity as well as a severe form of encephalopathy (Tiranti et al., 2009; Tiranti and Zeviani, 2013).
Even if the physiological sulfide degradation pathways are functioning normally, a steady-state plasma level of sulfide will produce heterogeneous cell/tissue sulfide ‘exposure levels’ for several reasons. First of all, a ‘Krogh cylinder’ type phenomenon (similar to that of oxygen) is likely to exist for sulfide, in which sulfide concentrations diminish as one moves away from the blood vessel and as one moves from the arterial to the venous side of the circulation. In addition, different cells and tissues have different levels of ‘anti-sulfide defences’ (e.g. sulfide binding and SOU in tissues). Moreover, within each cell, there may be subcellular organelles in which the degradation of sulfide is higher than in other areas of the cell. As discussed elsewhere (Bouillaud and Blachier, 2011), mitochondria are expected to produce steep decreases in the intracellular or transcellular sulfide gradients. Sulfide gradients and ‘anti-sulfide defences’ are also important in the context of the microflora resident in the colonic lumen and the colonic wall (Bouillaud and Blachier, 2011).
Notwithstanding the complex theoretical issues related to therapeutic sulfide administration, many pathophysiological conditions are associated with a relative deficiency of H2S (due to impaired production and/or enhanced degradation), and, in these circumstances, therapeutic H2S donation is be warranted, either to serve as a pharmacological replacement (as in diabetes, see above) or to induce transient metabolic suppression (as in the context of suspended animation, see above). It is hoped that future therapeutic H2S donation approaches will benefit from recent studies enabling the direct comparison of the doses and associated pharmacological actions of gaseous (inhalational) sulfide versus circulating, blood-borne sulfide. These studies yielded an approximate biological equivalency between 200 p.p.m. inhaled H2S and 10 mg·kg−1·h−1 i.v. infusion of a H2S solution (Wintner et al., 2010), and concluded that the therapeutic doses of sulfide in vivo are below those inhalational exposure levels that are associated with systemic toxicity.
Pharmacological exploitation of the mitochondrial effects of H2S: future directions
The above sections only represent selected examples of the pathophysiological and therapeutic aspects related to the complex mitochondrial modulatory effects of H2S. Based on several lines of experimental data (Hu et al., 2009; 2010; Pun et al., 2010; Caro et al., 2012; Guo et al., 2012b; Tang et al., 2012; Aslami et al., 2013b; Lu et al., 2013; Wen et al., 2013), it is likely that H2S as a mitochondrial protectant – similar to the example of diabetic endothelial dysfunction discussed above – also protects the mitochondria of neurons, stem cells, cardiac myocytes and various other cell types. It is also likely that bioenergetic effects play important roles in H2S-mediated angiogenesis (Cai et al., 2007; Papapetropoulos et al., 2009; Coletta et al., 2012), where it may serve to support the increased energy demand of the growing, migrating and dividing endothelial cells. At the opposite end of the spectrum is cancer therapy, in which high concentrations of H2S donors can cause inhibition of cell division and promotion of cell death (Lee et al., 2011; Tsubura et al., 2011; Wu et al., 2012; Kashfi and Olson, 2013), effects that are, at least in part, likely to be related to the inhibition of mitochondrial electron transport by high local concentrations of H2S. This latter concept does not conflict with the role of endogenously produced H2S in cancer, as the exogenously administered H2S donors produce much higher concentrations than endogenous sulfide levels, yielding a different biological response.
The interaction between the effects of H2S on mitochondrial function and the effects of H2S on cell signalling needs to be characterized in future studies as well. There are convincing data in the field of carbon monoxide (CO, another gaseous transmitter) showing that partial inhibition of mitochondrial electron transport, followed by a ‘leakage’ of ROS from the mitochondrial electron transport chain, plays a key role in the initiation of CO-dependent cellular signalling (Zuckerbraun et al., 2007). Whether similar processes are also at play in the case of H2S remains to be elucidated. In fact, the complex relationship between the three gasotransmitters (NO, CO and H2S) in the regulation of cellular signalling and cellular bioenergetics (Lane, 2006; Pun et al., 2010; Szabo, 2010) needs to be studied in further detail, in light of the effect of each of these transmitters on mitochondrial electron transport and glycolysis (Cooper and Brown, 2008; Pun et al., 2010). Furthermore, their emerging interdependence and mutual regulation in the context of many biological processes (e.g. Whiteman et al., 2006; Minamishima et al., 2009; Tomaskova et al., 2009; Yusof et al., 2009; Coletta et al., 2012; Carballal et al., 2013; Kondo et al., 2013; Polhemus et al., 2013) need to be further studied as well. We must also point out that in the current review, very little discussion was devoted to the ‘third’ H2S-producing enzyme, 3-MST (while its physiological roles have been detailed in the complementary article; Szabo et al., 2013a). At this point, there is essentially no information on the potential pathophysiological role of the 3-MST system; future work may identify pathophysiological conditions where the 3-MST system plays a role. The recent generation of the 3-MST deficient mice (Nagahara et al., 2013) may catalyse further work in this direction. Finally, the potential modulation of the H2S-dependent direct mitochondrial effects by other downstream effector pathways of H2S [such as cysteine modification (sulfhydration)] (Gadalla and Snyder, 2010), modulation of potassium channels (Zhao et al., 2001; Cheng et al., 2004; Cheang et al., 2010) and effects on calcium signalling (Bauer et al., 2010) remain to be explored in future studies.
There are a number of contentious, intensively debated issues in the field of H2S (for further reading, please see: Whiteman et al., 2011; Olson, 2013b,c), one of them being the circulating/plasma levels of H2S, and the methods used to measure it (especially the most commonly used method, the ‘methylene blue method’, which yields low- to- mid-micromolar plasma concentrations). As discussed elsewhere (Whitfield et al., 2008; Wintner et al., 2010; Whiteman et al., 2011; Olson, 2013b; Szabo et al., 2013a), there are various ‘pools’ of sulfide (or reactive sulfur species) in the circulation (free H2S gas being only a minor component of it, if any), and the methylene blue method is almost certainly measuring a net sum of these various pools, and it does not represent ‘free’ H2S levels. There may also be methodological issues that can result in a significant overestimation of the absorbance values detected by the methylene blue method (e.g. Van de Louw and Haouzi, 2012). Due to the fact that there are various biological ‘sinks’ of sulfide (e.g. in red blood cells), it is also difficult to estimate ‘steady-state’ levels of sulfide, or to be certain that such ‘steady-state’ levels even exist in biological systems (Olson, 2013c). Clearly, additional work is needed to clarify these issues and to improve the methods to detect H2S in biological systems. While this refinement is ongoing, we do not have a better option than to keep these limitations in mind, and to interpret the reported differences in the sulfide levels between two experimental groups (when reported in the same publication) as probably directionally correct, while remaining critical about the absolute values reported. Another issue that represents a severe limitation of the field is the lack of selective pharmacological tools. As discussed elsewhere (Whiteman et al., 2011; Asimakopoulou et al., 2013), the available compounds (PAG, AOAA, etc.) are neither particularly potent nor are they sufficiently selective or specific; they show cross-inhibition between the two pyridoxal 5′-phosphate (PLP)-dependent enzymes CSE and CBS, and they also inhibit a variety of other enzymes. One way to minimize this limitation is by using genetically modified animals or transient of permanent silencing of each enzyme (with the caveat that these tools, too, have certain limitations). While these issues remain to be refined, we must remain careful with the interpretation of most of the published studies utilizing these inhibitors (especially when they are not accompanied by corroborating studies using genetic tools).
Finally, we would like to emphasize that a substantial portion of the data reviewed in the current article, as well as its companion paper (Szabo et al., 2013a), stems from in vitro studies, and the number of studies investigating the stimulatory or inhibitory effect of exogenously administered or endogenously produced sulfide in vivo is limited (Table 2). As discussed elsewhere (Budde and Roth, 2011; Vozdek et al., 2012; Módis et al., 2013d), the model organism Caenorhabditis elegans provides a convenient system to study H2S-mediated biological regulatory mechanisms. In this organism, a CBS homologue enzyme is primarily responsible for endogenous H2S production (Vozdek et al., 2012). SiRNA-mediated silencing of this enzyme attenuates the bioenergetic function of C. elegans, consistent with the hypothesis that endogenous H2S production plays a stimulatory bioenergetic role (Szabo et al., 2013a). One known example of endogenously produced H2S suppressing mitochondrial function is the phenomenon of physiological hypoxia sensing (e.g. in the arterial chemoreceptors or the kidney) where, at biological sites associated with low O2 tension (e.g. the carotid body or the kidney medulla), the inhibition of complex IV by endogenous H2S (produced by CSE) plays a physiological regulatory role (Beltowski, 2010; Olson and Whitfield, 2010; Peng et al., 2010; Makarenko et al., 2012; Olson, 2013a). (Although it must be noted that the role of H2S in physiological hypoxia sensing remains a field of intensive research and debate, and other lines of data suggest that it may be a decreased oxidation of H2S during hypoxia, and the subsequent accumulation of H2S, and a subsequent signalling process that may be involved; see Olson, 2013c). Pharmacological inhibition of H2S production in the carotid body may be a potential future therapeutic approach for the therapy of chemoreceptor hypersensitivity and the associated cardiovascular imbalance, such as the one associated with chronic heart failure (Del Rio et al., 2013). It is also interesting to note that in a recent study, the CSE inhibitor PAG has been shown to block the hypoxia-induced decrease in oxygen uptake (VO2) in rats (Del Rio et al., 2013), perhaps indicative of a role endogenous H2S production in hypoxia-induced hypometabolism. One must keep in mind, nevertheless, that the selectivity of PAG is limited. Thus, it is hoped that the results of the above study will be confirmed and extended in future studies using CSE–/– mice. Additional studies in mammalian systems are necessary to clarify the complex bioenergetic roles of sulfide in various diseases in vivo and the interrelationship between bioenergetic regulation and the various other facets of sulfide biology (such as its diverse roles in the cardiovascular, central nervous and immune systems), in order to allow the design and testing of future therapeutic approaches.
The work of C. S. is supported by grants from the National Institutes of Health (P50GM060338), the Shriners Burns Hospitals (#8661), the American Diabetes Association (7-12-BS-184) and the John Sealy Memorial Endowment Fund for Biomedical Research. The work of P. R. is supported by the Deutsche Forschungsgemeinschaft (Klinische Forschergruppe 200) and the Land Baden-Württemberg (Innovationsfond Medizin). H. v. G. is supported by the Dutch Kidney Foundation (C08-2254). F. B and A. P. are supported by COST Action BM1005 (European Network of Gasotransmitters). The editorial assistance of Ms. Lili Szabo is appreciated.
Conflict of interest
C.S and M.H. are stockholders and corporate officers and A.P. is a stockholder and consultant to CBS Therapeutics Inc., a for-profit organization involved in the therapeutic exploitation of sulfide biosynthesis inhibitors for cancer therapy.